Survival Rate of Lung Adenocarcinoma Patients Receiving EGFR - Tyrosine Kinase Inhibitor Targeted Therapy
Keywords:EGFR-TKI, lung adenocarcinoma, survival rate
Globally, lung cancer is by far the leading cause of death by cancer-which contribute to 2.094 million death-with the highest toll from cancer being 1.8 million. Currently, lung cancer therapy has developed from chemotherapy to targeted therapy, such as Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI). This study aimed to assess the survival rate of adenocarcinoma cell lung cancer patients who received EGFR-TKI therapy at the Pulmonary Clinic of Dr. Saiful Anwar General Hospital Malang. This study was a retrospective study using patient medical records between 2017 and 2020. The data were processed and analyzed using the Chi-Square test. The number of samples was 117 patients consisting of 63 patients receiving Gefitinib therapy, 36 patients receiving Afatinib therapy, and 18 patients receiving Erlotinib therapy. There were no significant differences between variables of age, sex, smoking history, stage, and exon mutations with 1-year survival. Gefitinib therapy has a higher average survival time than Afatinib and Erlotinib. However, the 1-year survival rate (YSR) was highest on Afatinib. The Middle Survival (MS) of the three regimens is almost the same, about 300 days. Statistical data showed no relationship between survival and the treatment regimen given (p=0.187). The most common side effect of TKI is skin rash. This research should be carried out with a larger sample to minimize bias.
Torre LA, Siegel RL, and Jemal A. Lung Cancer Statistics. Advances in Experimental Medicine and Biology. 2016; 893: 1-9.
Zhang J, Li J, Xiong S, et al. Global Burden of Lung Cancer: Implications from Current Evidence. Annals of Cancer Epidemiology. 2021; 5(4): 1-2.
Ettinger DS, Wood DE, Aisner DL, et al. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(4): 504-535.
Upeksha G, Putra PP, Pratiwi SD, and Susanti MS. Hubungan antara Ekspresi P53 dan Ki67 sengan Berbagai Jenis Histopatologi Biopsi Bronkus pada Kasus Kanker Paru Primer. Jurnal Kesehatan Malang. 2016; 1(2): 1-8.
Yoneda K, Imanishi N, Ichiki Y, and Tanaka F. Treatment of Non-small Cell Lung Cancer with EGFR-mutations. Journal of UOEH. 2019; 41(2): 153-163.
Botting GM, Rastogi I, Chhabra G, Nlend M, and Puri N. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. 2015; 10(8): 1-17.
Ettinger DS, Wood DE, Akerley W, et al. Non–Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network. 2015; 13(5): 515-524.
Nyambe H, Santoso A, Tabri NA, Iskandar H, Ilyas M, and Wiriyansyah EP. The Survival Rate Comparison of Non Small Cell Lung Carcinoma Patients Who Are Given by Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor and those Given by First-Line Chemotherapy Treatment. Nusantara Medical Science Journal. 2021; 6(2): 102-115.
Asmis TR, Ding K, Seymour L, et al. Age and Comorbidity as Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials. Journal of Clinical Oncology. 2008; 26(1): 54-59.
Kligerman S and White C. Epidemiology of Lung Cancer in Women: Risk Factors, Survival, and Screening. American Journal of Roentgenology. 2011; 196(2): 287-295.
Peto J. That the Effects of Smoking should be Measured in Pack-Years: Misconceptions 4. British Journal of Cancer. 2012; 107(3): 406-407.
Wakelee HA, Chang ET, Gomez SL, et al. Lung Cancer Incidence in Never-Smokers. Journal of Clinical Oncology. 2007; 25(5): 472-478.
Ramalingam S, Dinan MA, and Crawford J. Survival Comparison In Patients With Stage IV Lung Cancer In Academic Versus Community Centers In The United States. Journal of Thoracic Oncology. 2018; 13(12): 1842-1850.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology. 2012; 13(3): 239-246.
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, and Henley SJ. Age and Cancer Risk: A Potentially Modifiable Relationship. American Journal of Preventive Medicine. 2014; 46(3): 7-15.
Liu M, Jiang G, Ding J, et al. Smoking Reduces Survival in Young Females with Lung Adenocarcinoma after Curative Resection. Medical Oncology. 2012; 29(2): 570-573.
Corrales L, Rosell R, Cardona AF, Martin C, Zatarain-Barrón ZL, and Arrieta O. Lung Cancer in Never Smokers: The Role of Different Risk Factors Other than Tobacco Smoking. Critical Reviews in Oncology/Hematology. 2020; 148: 1-8.
Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, and Dive C. Progress and Prospects of Early Detection in Lung Cancer. Open Biology. 2017; 7(9): 1-12.
Castellanos E, Feld E, and Horn L. Driven By Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 2017; 12(4): 612-623.
Krawczyk P, Kowalski DM, Ramlau R, et al. Comparison of the Effectiveness of Erlotinib, Gefitinib, and Afatinib for Treatment of Non‑Small Cell Lung Cancer in Patients with Common and Rare EGFR Gene Mutations. Oncology Letters. 2017; 13(6): 4433-4444.
Wulandari L, Febriani A, Fatmawati F, and Soegiarto G. Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor. Asian Journal of Oncology. 2018; 4(2): 48-53.
Sutandyo N, Hanafi A, and Jayusman M. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-Small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population. Chinese Journal of Lung Cancer. 2019 Sep 20; 22(9): 562-567.
Sari S, Andayani TM, Endarti D, and Widayati K. Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis. Jurnal Farmasi Klinik Indonesia. 2019; 8(4): 289-300.
- 2023-05-08 (2)
- 2023-02-27 (1)
LicenseAuthors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).